Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L.B. Seeff.
Natural history of hepatitis C.
Am J Med, 27 (1999), pp. 10S-15S
[2.]
L. Pagliaro, V. Peri, C. Linea, C. Cammà, M. Giunta, S. Magrin.
Natural history of chronic hepatitis C.
Ital J Gastroenterol Hepatol, 31 (1999), pp. 28-44
[3.]
T. Poynard, P. Bedossa, P. Opolon.
for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C.
Lancet, 349 (1997), pp. 825-832
[4.]
X. Forns, S. Ampurdanès, J.M. Sánchez-Tapias, M. Guilera, M. Sans, A. Sánchez-Fueyo, et al.
Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center.
J Hepatol, 35 (2001), pp. 265-271
[5.]
J. Neyts, P. Leyssen, E. De Clerq.
Infections with Flaviviridae.
Verh K Acad Geneeskd Belg, 61 (1999), pp. 661-697
[6.]
M.E. Major, S.M. Feinstone.
The molecular virology of hepatitis C.
Hepatology, 25 (1997), pp. 1527-1530
[7.]
L.F. He, D. Alling, T. Popkin, M. Shapiro, H.J. Alter, R.H. Purcell.
Determining the size of non-A, non-B hepatitis virus by filtration.
J Infect Dis, 156 (1987), pp. 636-640
[8.]
M. Hijikata, N. Kato, Y. Ootsuyama, M. Nakagawa, K. Shimotohno.
Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis.
Proc Nat Acad Sci USA, 88 (1991), pp. 5547-5551
[9.]
B. Rüster, S. Zeuzem, W.K. Roth.
Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma.
Biochem Biophys Res Commun, 219 (1996), pp. 911
[10.]
K. Moriya, H. Fujie, Y. Shintani, H. Yotsuyanagi, T. Tsutsumi, K. Ishibashi, et al.
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.
Nat Med, 4 (1998), pp. 1065
[11.]
M. Giménez-Barcons, S. Franco, Y. Suárez, X. Forns, S. Ampurdanès, F. Puig-Basagoiti, et al.
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.
Hepatology, 34 (2001), pp. 158-167
[12.]
R. Ralston, K. Thudium, K. Berger, C. Kuo, B. Gervase, J. Hall, et al.
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses.
J Virol, 67 (1993), pp. 6753-6761
[13.]
J. Bukh, R.H. Miller, R.H. Purcell.
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.
Semin Liver Dis, 15 (1995), pp. 41-54
[14.]
N. Kato, Y. Ootsuyama, T. Tanaka, M. Nakagawa, T. Nakazawa, K. Muraiso, et al.
Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.
Virus Res, 22 (1992), pp. 107-123
[15.]
P. Farci, A. Shimoda, D. Wong, T. Cabezon, D. De Gioannis, A. Strazzera, et al.
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.
Proc Natl Acad Sci USA, 93 (1996), pp. 15394
[16.]
Y.K. Shimizu, H. Igarashi, T. Kiyohara, T. Cabezon, P. Farci, R.H. Purcell, et al.
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures.
Virology, 223 (1996), pp. 409
[17.]
N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, et al.
Comparison of full-length sequences of interferon –sensitive and resistant hepatitis C virus 1b.
J Clin Invest, 96 (1995), pp. 224
[18.]
N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, et al.
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
N Engl J Med, 334 (1996), pp. 77
[19.]
J.C. Sáiz, F.X. López-Labrador, S. Ampurdanès, J. Dopazo, X. Forns, J.M. Sánchez-Tapias, et al.
The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b ans 3a isolates of hepatitis C virus.
J Infect Dis, 177 (1998), pp. 839-847
[20.]
N. Ogata, H.J. Alter, R.H. Miller, R.H. Purcell.
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.
Proc Natl Acad Sci USA, 88 (1991), pp. 3392-3396
[21.]
H. Okamoto, M. Kojima, S-I Okada, H. Yoshizawa, H. Iizuka, T. Tanaka, et al.
Genetic drift of hepatitis C virus during an 8,2-year infection in a chimpanzee: Variability and stability.
Virology, 190 (1992), pp. 894-899
[22.]
X. Forns, J. Bukh.
Methods for determining the hepatitis C virus genotype.
Viral Hepatitis Rev, 4 (1998), pp. 1
[23.]
G. Maertens, L. Stuyner.
Genotypes and genetic variation of hepatitis C virus.
The molecular medicine of viral hepatitis. Medical Science Series, pp. p183
[24.]
J. Bukh, S.U. Emerson, R.H. Purcell.
Genetic heterogeneity of hepatitis C virus and related viruses.
Viral hepatitis and liver disease, pp. p167
[25.]
M. Martell, J.I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, et al.
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.
J Virol, 66 (1992), pp. 3225
[26.]
R.H. Purcell.
Hepatitis C and its sequelae: the biology of hepatitis C virus and implications for its control.
Hepatitis C virus and its involment in the development of hepatocellular carcinoma, pp. p1-p113
[27.]
E. Domingo, L. Menéndez-Arias, M.E. Quiñones-Mateu, A. Holguin, M. Gutiérrez-Rivas, M.A. Martínez, et al.
Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants.
Prog Drug Res, 48 (1997), pp. 99-128
[28.]
A.J. Weiner, H.M. Geysen, C. Christopherson, J.E. Hall, T.J. Mason, G. Saracco, et al.
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Proc Natl Acad Sci USA, 89 (1992), pp. 3468
[29.]
P. Farci, H.J. Alter, D.C. Wong, R.H. Miller, S. Govindarajan, R. Engle, et al.
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.
Proc Natl Acad Sci USA, 91 (1994), pp. 7792
[30.]
J.C. Booth, U. Kumar, D. Webster, J. Monjardino, H.C. Thomas.
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients.
Hepatology, 27 (1998), pp. 223-227
[31.]
A. Weiner, A.L. Erickson, J. Kansopon, K. Crawford, E. Muchmore, A. Hughes, et al.
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.
Proc Natl Acad Sci USA, 92 (1995), pp. 2755-2759
[32.]
K.M. Chang, B. Rehermann, J.G. McHutchinson, C. Pasquinelli, S. Southwood, A. Sette, F.V. Chisari.
Immunological significance of cytotoxic T lymphocyte epitope variants in patient chronically infected by the hepatitis C virus.
J Clin Invest, 100 (1997), pp. 2376-2385
[33.]
S.L. Tsai, Y.M. Chen, M.H. Chen, C.Y. Huang, I.S. Sheen, C.T. Yeh, et al.
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity.
Gastroenterology, 115 (1998), pp. 954-965
[34.]
A. Takaki, M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, et al.
Cellular immune responses persist and humoral responses decrease two decades after recovery fron a single-source outbreak of hepatitis C.
Nat Med, 6 (2000), pp. 578-582
[35.]
Z. Hong, M. Beaudet-Miller, R.E. Landford, B. Guerra, J. Wright-Minogue, A. Skelton, et al.
Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees.
Virology, 256 (1999), pp. 36-44
[36.]
J. Bukh, M. Yanagi, S.U. Emerson, R.H. Purcell.
Course of infec-tion and evolution of monoclonal hepatitis C virus (HCV) strain H77 in chimpanzees transfected with RNA transcripts from an infectious cDNA clone.
Hepatology, 28 (1998), pp. 319A
[37.]
M.E. Major, K. Mihalik, J. Fernández, J. Seidman, D. Kleiner, A.A. Kolykhalov, et al.
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.
J Virol, 73 (1999), pp. 3317-3325
[38.]
X. Forns, R. Thimme, S. Govindarajan, S.U. Emerson, R.H. Purcell, F.V. Chisari, et al.
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees.
Proc Natl Acad Sci USA, 97 (2000), pp. 13318-13323
[39.]
D.R. Taylor, S.T. Shi, P.R. Romano, G.N. Barber, M.M. Lai.
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.
Science, 285 (1999), pp. 107-110
[40.]
K. Kiyosawa, T. Sodeyama, E. Tanaka, Y. Gibo, K. Yoshizawa, Y. Nakano, et al.
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.
Hepatology, 12 (1990), pp. 671-675
[41.]
M.J. Tong, N.S. al-Farra, A.R. Reikes, R.L. Co.
Clinical outcomes after transfusion –associated hepatitis C.
N Engl J Med, 332 (1995), pp. 1463-1466
[42.]
E. Kenny-Walsh.
and the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.
N Engl J Med, 340 (1999), pp. 1228-1233
[43.]
A.M. Di Bisceglie, Z.D. Goodman, K.G. Ishak, J.H. Hoofnagle, J.J. Melpolder, H.J. Alter.
Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis.
Hepatology, 14 (1991), pp. 969-974
[44.]
M.H. Khan, G.C. Farrell, K. Byth, R. Lin, M. Weltman, J. George, et al.
Which patients with hepatitis C develop liver complication?.
Hepatology, 31 (2000), pp. 513-520
[45.]
L.B. Seef, Z. Buskell-Bales, E.C. Wright, S.J. Durako, H.J. Alter, F.L. Iber, et al.
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group.
N Engl J Med, 327 (1992), pp. 1906-1911
[46.]
P. Farci, A. Shimoda, A. Coiana, G. Díaz, G. Peddis, J.C. Melpolder, et al.
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.
Science, 288 (2000), pp. 339-344
[47.]
M. Honda, S. Kaneko, A. Sakai, M. Unoura, S. Murakami, K. Kobayashi.
Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.
Hepatology, 20 (1994), pp. 1144
[48.]
S.J. Polyak, G. Faulkner, R.L. Carithers, L. Corey, D.R. Gretch.
Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy.
J Infect Dis, 175 (1997), pp. 1101
[49.]
M. Kobayashi, E. Tanaka, T. Sodeyama, A. Urushishara, A. Matsumoto, K. Kiyosawa.
The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses.
Hepatology, 23 (1996), pp. 695-699
[50.]
J.B. Nausbaum, S. Pol, B. Nalpas, P. Landais, P. Berthelot, C. Brechot.
and the collaborative study group. Hepatitis C virus 1 b in France and Italy.
Ann Intern Med, 122 (1995), pp. 161
[51.]
E. Silini, R. Bottelli, M. Asti, S. Bruno, M.E. Candusso, S. Brambilla, et al.
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study.
Gastroenterology, 111 (1996), pp. 199
[52.]
F.X. López-Labrador, S. Ampurdanès, X. Forns, A. Castells, J.C. Sáiz, J. Costa, et al.
Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma.
J Hepatol, 27 (1997), pp. 959-965
[53.]
G.L. Davis, J.Y.N. Lau.
Factors predictive of a beneficial response to therapy of hepatitis.
Hepatology, 26 (1997), pp. 1225-1275
[54.]
A. El Zayadi, P. Simmonds, H. Dabbous, L. Prescot, O. Selim, A. Ahdy, et al.
Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4.
J Viral Hepat, 3 (1996), pp. 261
[55.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1493
[56.]
J.G. McHutchinson, C.G. Stuart, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485
[57.]
M. Berenguer, T.L. Wright.
Hepatitis C and liver transplantation.
Gut, 45 (1999), pp. 159-163
[58.]
D. Samuel, C. Feray.
Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues.
J Viral Hepat, 7 (2000), pp. 87-92
[59.]
M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, D. Carrasco, et al.
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Hepatology, 29 (1999), pp. 250-256
[60.]
M. Martell, J.I. Esteban, J. Quer, V. Vargas, R. Esteban, J. Guardia, et al.
Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation.
J Virol, 68 (1994), pp. 3425
[61.]
D.R. Gretch, S.J. Polyak, J.J. Wilson, R.L. Carithers, J.D. Perkins, L. Corey.
Tracking hepatitis C virus quasispecies in symptomatic and asymptomatic liver transplant recipients.
J Virol, 70 (1996), pp. 7622-7631
[62.]
T. Laskus, L.F. Wanf, J. Rakela, H. Vargas, A.D. Pinna, A.C. Tsamandas, et al.
Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors.
Virology, 220 (1996), pp. 171
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
